Key Points
- CEO sale: CEO Bradley Campbell sold 77,926 shares on Dec. 15 at an average price of $10.86 for proceeds of $846,276.36, cutting his direct stake to 1,129,782 shares (a 6.45% ownership reduction).
- Recent results: Amicus beat estimates last quarter with EPS of $0.17 vs. $0.12 expected and revenue of $169.06M (up 19.5% year-over-year), though the company still showed a negative net margin.
- Analyst sentiment: Analysts are generally positive — MarketBeat shows a consensus rating of "Moderate Buy" with a $17.29 target, and several firms (JPMorgan, Citigroup, Needham) have raised ratings or targets recently.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $11.00, for a total transaction of $282,073.00. Following the completion of the sale, the insider directly owned 271,332 shares in the company, valued at approximately $2,984,652. This trade represents a 8.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
David Michael Clark also recently made the following trade(s):
- On Monday, November 24th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $258,994.30.
- On Tuesday, November 4th, David Michael Clark sold 25,643 shares of Amicus Therapeutics stock. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93.
Amicus Therapeutics Stock Performance
Shares of NASDAQ FOLD traded down $0.24 during midday trading on Thursday, hitting $10.76. 220,948 shares of the company's stock were exchanged, compared to its average volume of 4,295,684. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $11.14. The firm has a market cap of $3.32 billion, a P/E ratio of -268.03 and a beta of 0.46. The stock's 50 day moving average price is $9.31 and its 200-day moving average price is $7.75. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same quarter in the previous year, the firm posted $0.10 EPS. The firm's quarterly revenue was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.
Institutional Investors Weigh In On Amicus Therapeutics
Several hedge funds have recently bought and sold shares of FOLD. PNC Financial Services Group Inc. increased its holdings in shares of Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 3,497 shares during the period. Invesco Ltd. boosted its stake in shares of Amicus Therapeutics by 4.1% during the 1st quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company's stock valued at $21,717,000 after buying an additional 105,856 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Amicus Therapeutics by 167.6% during the 1st quarter. Russell Investments Group Ltd. now owns 142,569 shares of the biopharmaceutical company's stock valued at $1,163,000 after acquiring an additional 89,287 shares in the last quarter. Aberdeen Group plc increased its stake in shares of Amicus Therapeutics by 14.9% in the first quarter. Aberdeen Group plc now owns 1,586,609 shares of the biopharmaceutical company's stock worth $12,947,000 after acquiring an additional 205,834 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Amicus Therapeutics by 2.6% during the first quarter. Wellington Management Group LLP now owns 29,200,617 shares of the biopharmaceutical company's stock valued at $238,277,000 after purchasing an additional 738,623 shares during the last quarter.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on FOLD shares. Needham & Company LLC raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price objective on the stock in a research note on Thursday, September 18th. Wall Street Zen upgraded shares of Amicus Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Monday. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Thursday, November 6th. Finally, Citigroup began coverage on Amicus Therapeutics in a research report on Wednesday. They set a "buy" rating and a $17.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $17.29.
View Our Latest Stock Analysis on Amicus Therapeutics
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
